Patients must have an estimated survival greater or equal to  months
Participants with active infection(s) for which they are receiving drug treatment unless the clinical status is judged to be stable and survival is estimated to be at least  weeks
ECOG performance status of  -  and estimated survival of at least  months
Estimated survival of at least  weeks;
Patients must have at least one of the following for a diagnosis/disease status:\r\n* Unresectable disease\r\n* Metastatic disease\r\n* Medically unfit for surgical resection but with an expected survival of >  months, Eastern Cooperative Oncology Group (ECOG) <  and New York Heart Association (NYHA) status =< II\r\n* Disease where no conventional therapy leads to a survival benefit >  months in the respective cohort and line of therapy for which the patient is otherwise eligible\r\n* Actionable alterations determined by FoundationOne
Presence of any other medical complication that implies survival of less than six months
For known primary, disease-specific graded prognostic assessment (ds-GPA) estimated median survival no less than  months
For unknown primary, graded prognostic assessment (GPA) estimated median survival no less than  months
Patients who have a known primary and have an estimated median survival less than  months per ds-GPA
Patients who have an unknown primary and have an estimated median survival less than  months per GPA
Estimated survival >=  months
Participants with a serious medical illness that may limit survival to less than  months
No known Food and Drug Administration (FDA) -approved therapy available that is expected to prolong survival by greater than  months
Predicted survival of >  months
Surgeon's estimated survival >=  month
Estimated survival <  month
Patients with an estimated survival of less than three months.
Estimated survival of at least  weeks
Estimated survival of at least  months
Patients must have a reasonable expectation of ?  months survival
Estimated survival ?  months.
An estimated progression-free survival of less than one year
Survival expectation of  weeks or longer after starting study drug
Similar condition with an expectation of > % five-year disease-free survival
Survival expectation of  weeks or longer after starting study drug.
Patients must have an estimated survival greater than or equal to  months
Presence of any other medical complications that imply a survival of less than six months
No known Food and Drug Administration (FDA)-approved therapy available thats expected to prolong survival by greater than  months
Patients with an estimated survival of less than one year are not eligible
Have a -year survival rate of % or greater as deemed by their oncologist, surgeon, or other relevant attending physician (suggesting a reasonable rate of cure or prolonged medical survival with state-of-the-art medical care).
Survival less than  months after surgery (either predicted survival before surgery or actual survival after surgery <  months)
Patients with an ECOG performance status of , , or , and estimated survival of >  weeks.
If survival is deemed less than  months for any medical condition
Estimated survival of at least  months.
Patient may have distant metastatic disease provided the estimated survival is at least  year